Marshall Wace, LLP Puma Biotechnology, Inc. Transaction History

Marshall Wace, LLP

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.92 - $5.83 $112,145 - $223,906	-38,406 Reduced 16.1%	200,085 $652,000
Q1 2024 May 15, 2024	SELL	$4.29 - $7.4 $472,461 - $814,969	-110,131 Reduced 31.59%	238,491 $1.26 Million
Q4 2023 Feb 14, 2024	BUY	$2.23 - $4.49 $299,732 - $603,496	134,409 Added 62.75%	348,622 $1.51 Million
Q3 2023 Nov 14, 2023	SELL	$2.63 - $4.09 $27,825 - $43,272	-10,580 Reduced 4.71%	214,213 $563,000
Q2 2023 Aug 14, 2023	BUY	$2.6 - $3.58 $132,540 - $182,497	50,977 Added 29.33%	224,793 $793,000
Q1 2023 May 15, 2023	SELL	$2.21 - $4.82 $325,844 - $710,665	-147,441 Reduced 45.9%	173,816 $537,000
Q4 2022 Feb 14, 2023	BUY	$2.12 - $5.08 $681,064 - $1.63 Million	321,257 New	321,257 $1.36 Million
Q1 2022 May 16, 2022	SELL	$2.13 - $3.24 $845,539 - $1.29 Million	-396,967 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.85 - $6.58 $1.07 Million - $2.46 Million	373,691 Added 1605.48%	396,967 $1.21 Million
Q3 2021 Nov 15, 2021	BUY	$6.63 - $9.39 $154,319 - $218,561	23,276 New	23,276 $163,000
Q2 2019 Aug 14, 2019	SELL	$12.3 - $35.76 $83,492 - $242,738	-6,788 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$20.77 - $42.37 $104,016 - $212,188	-5,008 Reduced 42.46%	6,788 $263,000
Q4 2018 Feb 14, 2019	BUY	$20.07 - $46.7 $236,745 - $550,873	11,796 New	11,796 $241,000
Q3 2018 Nov 14, 2018	SELL	$41.2 - $59.85 $201,550 - $292,786	-4,892 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$48.3 - $68.25 $236,283 - $333,879	4,892 New	4,892 $289,000

102

29M

60.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $138M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.